TP53 and osteosarcoma: The combination of Wee1 inhibitor with chemotherapy has exhibited synergistic cytotoxicity in several types of mutant TP53 cancers, including head and neck cancer, osteosarcoma, breast cancer, and ovarian cancer [34,35,36,37].